article thumbnail

STAT+: FTC says pharmacy benefit managers are stonewalling requests for information

STAT

antitrust regulators into pharmaceutical industry middlemen has been stymied because the companies have failed to provide many of the documents that, in some cases, were requested as far back as June 2022. A much-anticipated inquiry by U.S.

article thumbnail

Despite federal disclosure rules, state prisons hide information on hepatitis C-related deaths

STAT

It’s virtually impossible to get information from states and correctional facilities about why people die in prison.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Opinion: STAT+: Some countries are moving to digital prescription drug information for patients. The U.S. shouldn’t follow suit

STAT

Having all of these details in accessible, printed documents keeps patients informed and mitigates the risk of medication errors. However, there’s a growing movement across the world to eliminate printed medication information, making it harder for patients to learn about the drugs that, in many cases, save their lives.

article thumbnail

STAT+: Novartis claims Takeda is stonewalling efforts to review trade secrets taken by a former employee

STAT

Novartis has gone to court to gain access to Takeda Pharmaceutical documents over concerns that a former employee took trade secrets with him to his new job at the rival drugmaker. Continue to STAT+ to read the full story…

article thumbnail

Patients’ social needs often get lost in health records. Generative AI could help

STAT

Generative AI’s earliest applications in medicine have largely focused on curing not patients, but the plague of productivity physicians lose to digital documentation. Read the rest…

article thumbnail

STAT+: Viatris executive is charged with insider trading scheme involving a friend and former colleague

STAT

In court documents, federal authorities alleged that Ramkumar Rayapureddy, the chief information officer at the drug company, which was previously known as Mylan, provided “material” information to Dayakar Mallu, who also worked in the IT department.

article thumbnail

STAT+: BrainStorm’s case for ALS approval relies on ‘grossly deficient’ data, FDA finds

STAT

The Food and Drug Administration said Monday that it has deep reservations about NurOwn , an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.